patent-law
(3)
Karl Ruping
Karl Ruping is the founder and CEO of Tiba Biotech, a Cambridge, Massachusetts company developing biodegradable nanoparticle delivery systems for RNA vaccines and therapeutics. He also runs incTANK Ventures, a seed fund spun out of MIT and Boston-area research labs, and sits at Harvard's Asia Center as an associate working on international patent policy. Lawyer, computational scientist, financier, and operator wrapped into one resume.
Andrew Chadeayne
Andrew Chadeayne is the founder and CEO of CaaMTech, an Issaquah, Washington psychedelic pharmaceutical company building safer, patentable psychedelic-inspired medicines. A chemist (PhD, Cornell) and patent attorney (JD, George Washington) who began his career proving sugar is addictive through opioid pathways, he has filed more than 100 patent applications mapping the chemistry of psilocybin, tryptamines and other psychedelics. His strategy is to expand 'the universe of available compounds' rather than bet on a single molecule, giving researchers a toolbox of characterized psychedelics for mental health treatment.
Kanav Hasija
Kanav Hasija is Co-Founder and CEO of MeltPlan, an AI-native preconstruction planning platform backed by Bessemer Venture Partners. A serial entrepreneur who co-built Innovaccer into a $3.2B healthcare data unicorn, he now applies the same data-platform playbook to construction — where fragmented planning and late-stage surprises cost billions annually. MeltPlan's tools (Melt Code, Melt Takeoff) bring AI-powered code compliance and quantity estimation to architects, contractors, and owners before the first shovel breaks ground.